Daxdilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Daxdilimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 2
Highest phase
9
Registered trials
5
Result records
4
Matched deals
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Daxdilimab can convert its Monoclonal antibody profile and LILRA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Daxdilimab (query alias: daxdilimab) |
|---|---|
| Modality / target | Monoclonal antibody; LILRA4; LILRA4 inhibitors, Dendritic cells modulators |
| Highest global status | Phase 2 |
| Originator | SBI Biotech Co., Ltd. |
| Active developers | Amgen, Inc., Viela Bio, Inc., Horizon Therapeutics Ireland DAC |
The MCP disease footprint includes Dermatomyositis, Idiopathic Inflammatory Myopathies, Alopecia Areata. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05430854 | Phase 2 | Terminated | 155 | Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) |
| NCT05591222 | Phase 2 | Terminated | 72 | Mean Change in Cutaneous Lupus Erythematosus Disease and Severity Index-Activity (CLASI-A) Score from Baseline to Week 24 |
| NCT05540665 | Phase 2 | Terminated | 19 | Percentage of Participants Who Achieved CRR at Week 48 Through Week 52 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis
Phase 2; n=19; evaluation: not stated. Reported fields: -; -; -
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
Phase 2; n=30; evaluation: not stated. Reported fields: -; Percent Change From Baseline in SALT Score at Week 24(Mean) = -12.6 percent change in score on a scale (Standard Deviation, 35.15); -
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Phase 2; n=214; evaluation: Positive. Reported fields: LLDAS(W48) = 22.0 % ; LLDAS(W48) = 33.7 % ; LLDAS(W48) = 17.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Daxdilimab addresses Dermatomyositis, Idiopathic Inflammatory Myopathies, Alopecia Areata. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-02-01 | Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. | Phase 3 | Financial terms not disclosed |
| 2018-03-06 | Viela Bio partners with SBI Biotech for the development of VIB-7734, targeting systemic lupus erythematosus and autoimmune diseases. | Phase 1 | US$137.0M stated total |
| 2018-02-01 | MedImmune spin out six molecules from its early-stage inflammation and autoimmunity programmes into Viela Bio | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
